Securities class action against Valeant Pharmaceuticals International, Inc. and certain of its former and current officers and/or directors to recover damages for losses plaintiffs have suffered on Valeant common stock purchased or acquired by Plaintiffs between September 28, 2015 and August 10, 2016, pursuant to the Securities Exchange Act of 1934.
|Lead Plaintiff Deadline||11/26/17|
Brief Company Profile
Valeant Pharmaceuticals International, Inc. operates as a pharmaceutical and medical device company worldwide. It operates in three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products.
The company was formerly known as Biovail Corporation and changed its name to Valeant Pharmaceuticals International, Inc. in September 2010. The company was founded in 1983 and is headquartered in Laval, Canada.
|Class Period||9/28/15 - 8/10/16|
|Court||D. New Jersey|
|Judge||Michael A. Shipp, presiding|
|Plaintiff(s)||PENTWATER EQUITY OPPORTUNITIES MASTER FUND LTD.; PENTWATER EVENT DRIVEN CAYMAN FUND LTD; PENTWATER MERGER ARBITRAGE MASTER FUND LTD.; PWCM MASTER FUND LTD.; OCEANA MASTER FUND LTD.; and LMA SPC FOR AND ON BEHALF OF MAP 98 SEGREGATED PORTFOLIO|
|Defendant(s)||VALEANT PHARMACEUTICALS INTERNATIONAL, INC., J. MICHAEL PEARSON, HOWARD B. SCHILLER, ROBERT L. ROSIELLO, DEBORAH JORN, ARI S. KELLEN, and TANYA CARRO|